Abstract
If a pheochromocytoma is clinically suspected or diagnosed, the goal of imaging is lesion localization, and there are anatomical and functional imaging modalities used for it. CT is the anatomical modality of choice to identify an adrenal lesion or the less common extra-adrenal paragangliomas, and MIBG is the most widely used functional modality. Paragangliomas are frequently intra-abdominal (Blake et al. 24:S87–99, 2004), located in the retroperitoneum near the level of the SMA origin or aortic bifurcation (organ of Zuckerkandl) (Mayo-Smith et al. 21:995–1012, 2001). However, they may be encountered anywhere from the base of the skull to the urinary bladder, as they develop in the chromaffin tissue of the sympathetic nervous system (Blake et al. 24:S87–99, 2004), and other common extra-adrenal locations include the bladder wall, other parts of the retroperitoneum, heart, mediastinum, carotid body, and glomus jugulare body. MR is an alternate anatomical imaging localization modality; however, due to the greater availability, better spatial resolution and lower cost, CT remains the preferred initial anatomical imaging modality. The functional imaging modalities include nuclear medicine exams with a variety of radiotracers, including more specific tracers being developed as the biochemical characteristics of the tumors are better understood. Functional imaging has higher specificity and has great value as a confirmatory exam, and also to evaluate the possibility of multifocal lesions in abdominal and extra-abdominal locations, as well as metastatic lesions.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Blake MA, Kalra MK, Maher MM, Sahani DV, Sweeney AT, Mueller PR, et al. Pheochromocytoma: an imaging chameleon. Radiographics Rev Publ Radiol Soc North Am Inc. 2004;24(Suppl 1):S87–99.
Mayo-Smith WW, Boland GW, Noto RB, Lee MJ. State-of-the-art adrenal imaging. Radiographics Rev Publ Radiol Soc North Am Inc. 2001;21(4):995–1012.
Choyke PL. ACR appropriateness criteria on incidentally discovered adrenal mass. J Am Coll Radiol JACR. 2006;3(7):498–504.
Miller JC, Blake MA, Boland GW, Copeland PM, Thrall JH, Lee SI. Adrenal masses. J Am Coll Radiol JACR. 2009;6(3):206–11.
Weber AL, Janower ML, Griscom T. Radiologic and clinical evaluation of Pheochromocytoma in children: report of 6 cases. Radiology. 1967;88(1):117–23.
Szolar DH, Korobkin M, Reittner P, Berghold A, Bauernhofer T, Trummer H, et al. Adrenocortical carcinomas and adrenal pheochromocytomas: mass and enhancement loss evaluation at delayed contrast-enhanced CT. Radiology. 2005;234(2):479–85.
Mukherjee JJ, Peppercorn PD, Reznek RH, Patel V, Kaltsas G, Besser M, et al. Pheochromocytoma: effect of nonionic contrast medium in CT on circulating catecholamine levels. Radiology. 1997;202(1):227–31.
McCollough CH, Primak AN, Braun N, Kofler J, Yu L, Christner J. Strategies for reducing radiation dose in CT. Radiol Clin N Am. 2009;47(1):27–40.
Mettler FA Jr, Huda W, Yoshizumi TT, Mahesh M. Effective doses in radiology and diagnostic nuclear medicine: a catalog. Radiology. 2008;248(1):254–63.
Lee TH, Slywotzky CM, Lavelle MT, Garcia RA. Best cases from the AFIP. Radiographics Rev Publ Radiol Soc North Am Inc. 2002;22(4):935–40.
Adam SZ, Nikolaidis P, Horowitz JM, Gabriel H, Hammond NA, Patel T, et al. Chemical shift MR imaging of the adrenal gland: principles, pitfalls, and applications. Radiographics Rev Publ Radiol Soc North Am Inc. 2016;36(2):414–32.
Yoon JK, Remer EM, Herts BR. Incidental pheochromocytoma mimicking adrenal adenoma because of rapid contrast enhancement loss. AJR Am J Roentgenol. 2006;187(5):1309–11.
Patel J, Davenport MS, Cohan RH, Caoili EM. Can established CT attenuation and washout criteria for adrenal adenoma accurately exclude pheochromocytoma? AJR Am J Roentgenol. 2013;201(1):122–7.
Shaaban AM, Rezvani M, Tubay M, Elsayes KM, Woodward PJ, Menias CO. Fat-containing retroperitoneal lesions: imaging characteristics, localization, and differential diagnosis. Radiographics Rev Publ Radiol Soc North Am Inc. 2016;36(3):710–34.
Goenka AH, Shah SN, Remer EM, Berber E. Adrenal imaging: a primer for oncosurgeons. J Surg Oncol. 2012;106(5):543–8.
Jacques AE, Sahdev A, Sandrasagara M, Goldstein R, Berney D, Rockall AG, et al. Adrenal phaeochromocytoma: correlation of MRI appearances with histology and function. Eur Radiol. 2008;18(12):2885–92.
Al Bunni F, Deganello A, Sellars ME, Schulte KM, Al-Adnani M, Sidhu PS. Contrast-enhanced ultrasound (CEUS) appearances of an adrenal phaeochromocytoma in a child with von Hippel-Lindau disease. J Ultrasound. 2014;17(4):307–11.
Mittendorf EA, Evans DB, Lee JE, Perrier ND. Pheochromocytoma: advances in genetics, diagnosis, localization, and treatment. Hematol Oncol Clin North Am. 2007;21(3):509–25. ix
Blanchet EM, Martucci V, Pacak K. Pheochromocytoma and paraganglioma: current functional and future molecular imaging. Front Oncol. 2011;1:58.
Sisson JC, Frager MS, Valk TW, Gross MD, Swanson DP, Wieland DM, et al. Scintigraphic localization of pheochromocytoma. N Engl J Med. 1981;305(1):12–7.
Huynh TT, Pacak K, Brouwers FM, Abu-Asab MS, Worrell RA, Walther MM, et al. Different expression of catecholamine transporters in phaeochromocytomas from patients with von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2. Eur J Endocrinol. 2005;153(4):551–63.
Shulkin BL, Shapiro B, Francis IR, Dorr R, Shen SW, Sisson JC. Primary extra-adrenal pheochromocytoma: positive I-123 MIBG imaging with negative I-131 MIBG imaging. Clin Nucl Med. 1986;11(12):851–4.
Timmers HJ, Chen CC, Carrasquillo JA, Whatley M, Ling A, Havekes B, et al. Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. J Clin Endocrinol Metab. 2009;94(12):4757–67.
Fottner C, Helisch A, Anlauf M, Rossmann H, Musholt TJ, Kreft A, et al. 6-18F-fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to 123I-metaiodobenzyl-guanidine scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas: correlation with vesicular monoamine transporter expression. J Clin Endocrinol Metab. 2010;95(6):2800–10.
Bombardieri E, Giammarile F, Aktolun C, Baum RP, Bischof Delaloye A, Maffioli L, et al. 131I/123I-metaiodobenzylguanidine (mIBG) scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging. 2010;37(12):2436–46.
de Herder WW, Lamberts SW. Somatostatin and somatostatin analogues: diagnostic and therapeutic uses. Curr Opin Oncol. 2002;14(1):53–7.
Shulkin BL, Thompson NW, Shapiro B, Francis IR, Sisson JC. Pheochromocytomas: imaging with 2-[fluorine-18]fluoro-2-deoxy-D-glucose PET. Radiology. 1999;212(1):35–41.
Hofman MS, Hicks RJ. Moving beyond “Lumpology”: PET/CT imaging of Pheochromocytoma and Paraganglioma. Clin Cancer Res Off J Am Assoc Cancer Res. 2015;21(17):3815–7.
Maecke HR, Hofmann M, Haberkorn U. (68)Ga-labeled peptides in tumor imaging. J Nucl Med Off Publ Soc Nucl Med. 2005;46(Suppl 1):172s–8s.
Schreiter NF, Brenner W, Nogami M, Buchert R, Huppertz A, Pape UF, et al. Cost comparison of 111In-DTPA-octreotide scintigraphy and 68Ga-DOTATOC PET/CT for staging enteropancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2012;39(1):72–82.
Luster M, Karges W, Zeich K, Pauls S, Verburg FA, Dralle H, et al. Clinical value of 18F-fluorodihydroxyphenylalanine positron emission tomography/computed tomography (18F-DOPA PET/CT) for detecting pheochromocytoma. Eur J Nucl Med Mol Imaging. 2010;37(3):484–93.
Treglia G, Cocciolillo F, de Waure C, Di Nardo F, Gualano MR, Castaldi P, et al. Diagnostic performance of 18F-dihydroxyphenylalanine positron emission tomography in patients with paraganglioma: a meta-analysis. Eur J Nucl Med Mol Imaging. 2012;39(7):1144–53.
Mann GN, Link JM, Pham P, Pickett CA, Byrd DR, Kinahan PE, et al. [11C]metahydroxyephedrine and [18F]fluorodeoxyglucose positron emission tomography improve clinical decision making in suspected pheochromocytoma. Ann Surg Oncol. 2006;13(2):187–97.
Trampal C, Engler H, Juhlin C, Bergstrom M, Langstrom B. Pheochromocytomas: detection with 11C hydroxyephedrine PET. Radiology. 2004;230(2):423–8.
Yamamoto S, Hellman P, Wassberg C, Sundin A. 11C-hydroxyephedrine positron emission tomography imaging of pheochromocytoma: a single center experience over 11 years. J Clin Endocrinol Metab. 2012;97(7):2423–32.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Harmath, C.B., Savas, H. (2018). Localization of Pheochromocytoma and Paraganglioma. In: Landsberg, L. (eds) Pheochromocytomas, Paragangliomas and Disorders of the Sympathoadrenal System. Contemporary Endocrinology. Humana Press, Cham. https://doi.org/10.1007/978-3-319-77048-2_7
Download citation
DOI: https://doi.org/10.1007/978-3-319-77048-2_7
Published:
Publisher Name: Humana Press, Cham
Print ISBN: 978-3-319-77047-5
Online ISBN: 978-3-319-77048-2
eBook Packages: MedicineMedicine (R0)